Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 92

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H1 2018

Summary

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli.

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 7 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Prostate Cancer, Malignant Mesothelioma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Amyotrophic Lateral Sclerosis, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Bone Sarcoma, Burkitt Lymphoma, Cervical Cancer, Chondrosarcoma, Colorectal Cancer, Dedifferentiated Liposarcoma, Duchenne Muscular Dystrophy, Endometrial Cancer, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Fallopian Tube Cancer, Follicular Lymphoma, Hematological Tumor, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Liposarcoma, Mantle Cell Lymphoma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Sclerosis, Natural Killer Cell Lymphomas, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Primary Mediastinal B-Cell Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Respiratory Syncytial Virus (RSV) Infections, Rheumatoid Arthritis, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Synovial Sarcoma, Systemic Lupus Erythematosus, Thymoma (Thymic Epithelial Tumor), Traumatic Brain Injury, Unspecified Influenza Virus Infections and Waldenstrom Macroglobulinemia.

The latest report Exportin 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)

- The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Overview
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Companies Involved in Therapeutics Development
Biogen Inc
CanBas Co Ltd
Karyopharm Therapeutics Inc
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug Profiles
BIIB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBS-9106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eltanexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-251 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-276 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verdinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant Products
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Discontinued Products
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Product Development Milestones
Featured News & Press Releases
Jun 01, 2018: Karyopharm to Present Selinexor Phase 2/3 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting
May 17, 2018: Stemline Therapeutics Announces Presentation of SL-801 Clinical Data at the Upcoming ASCO Annual Meeting
May 17, 2018: Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting
May 16, 2018: Karyopharm to Present Selinexor Phase 2 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting
Apr 30, 2018: Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma
Apr 26, 2018: Stemline Therapeutics Announces Clinical Presentation of SL-801 at the Upcoming ASCO Annual Meeting
Apr 10, 2018: Karyopharm's Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Penta-Refractory Multiple Myeloma
Mar 19, 2018: Karyopharm to Present Preclinical Data on Selinexor at the American Association for Cancer Research 2018 Annual Meeting
Mar 19, 2018: Karyopharm to Present Preclinical Data On Eltanexor at the American Association for Cancer Research 2018 Annual Meeting
Jan 31, 2018: Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy
Dec 10, 2017: Karyopharm Presents Data On Selinexor (KPT-330) At The American Society of Hematology 2017 Annual Meeting
Dec 10, 2017: Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting
Dec 10, 2017: Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting
Nov 01, 2017: Karyopharm to Present Phase 1b/2 STOMP Clinical Data at the American Society of Hematology 2017 Annual Meeting
Sep 20, 2017: Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Biogen Inc, H1 2018
Pipeline by CanBas Co Ltd, H1 2018
Pipeline by Karyopharm Therapeutics Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
  • Global Emollient Market Research Report 2018
    Published: 19-Jun-2018        Price: US 2900 Onwards        Pages: 96
    This report studies the global Emollient market status and forecast, categorizes the global Emollient market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Emollient is the medical word for a moisturizer. Emollients trap moisture in the skin and form a Protective oily layer on the outer skin which helps skin repair and improves skin hy......
  • Global Liquid Biopsy Products Market Research Report 2018
    Published: 19-Jun-2018        Price: US 2900 Onwards        Pages: 91
    This report studies the global Liquid Biopsy Products market status and forecast, categorizes the global Liquid Biopsy Products market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Liquid biopsies are a sequencing-based technology used to screen blood for tiny fragments of genetic material released by cancer tissue, known as circulating tum......
  • Global Squalane Market Research Report 2018
    Published: 19-Jun-2018        Price: US 2900 Onwards        Pages: 94
    This report studies the global Squalane market status and forecast, categorizes the global Squalane market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China and other regions (India, Southeast Asia, Central & South America, and Middle East & Africa). Squalane is of a molecular formula C30H62 and has a specific stereochemical conformation. Squalane is traditionally sourced from ......
  • Global Microencapsulation Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Jun-2018        Price: US 3480 Onwards        Pages: 131
    Microencapsulation is a process in which tiny particles or droplets are surrounded by a coating to give small capsules, of many useful properties. In general, it is used to incorporate food ingredients, enzymes, cells or other materials on a micro metric scale. Microencapsulation usually refers to sizes ranging from 1 µm to 1 mm. Scope of the Report: This report focuses on the Microencapsulation in global market, especially in North America, Europe and Asia-Pacific,......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Microencapsulation Market 2018, Forecast to 2023
    Published: 18-Jun-2018        Price: US 4880 Onwards        Pages: 136
    Microencapsulation is a process in which tiny particles or droplets are surrounded by a coating to give small capsules, of many useful properties. In general, it is used to incorporate food ingredients, enzymes, cells or other materials on a micro metric scale. Microencapsulation usually refers to sizes ranging from 1 µm to 1 mm. Scope of the Report: This report focuses on the Microencapsulation in global market, especially in North America, Europe and Asia-Pacific,......
  • Global Halal Pharmaceuticals Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Jun-2018        Price: US 3480 Onwards        Pages: 136
    Halal pharmaceuticals are those medicines that stringently adhere to Shariah law. More specifically, halal pharmaceuticals refer to medicines that should not contain any parts of animals (dogs, pigs and ones particularly with pointed teeth), insects (bees), alcohol and other substances prohibited as 'haram' under the Shariah law. Scope of the Report: This report focuses on the Halal Pharmaceuticals in global market, especially in North America, Europe and Asia-Pacif......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Halal Pharmaceuticals Market 2018, Forecast to 2023
    Published: 18-Jun-2018        Price: US 4880 Onwards        Pages: 135
    Halal pharmaceuticals are those medicines that stringently adhere to Shariah law. More specifically, halal pharmaceuticals refer to medicines that should not contain any parts of animals (dogs, pigs and ones particularly with pointed teeth), insects (bees), alcohol and other substances prohibited as 'haram' under the Shariah law. Scope of the Report: This report focuses on the Halal Pharmaceuticals in global market, especially in North America, Europe and Asia-Pacif......
  • Global Physiological Saline Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Jun-2018        Price: US 3480 Onwards        Pages: 136
    Physiological Saline is a mixture of sodium chloride in water and has a number of uses in medicine. Applied to the affected area it is used to clean wounds, help remove contact lenses, and help with dry eyes. By injection into a vein it is used to treat dehydration such as from gastroenteritis and diabetic ketoacidosis. It is also used to dilute other medications to be given by injection. Note: In this report, the unit should be bottle or bag, which depends on the package of the p......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Physiological Saline Market 2018, Forecast to 2023
    Published: 18-Jun-2018        Price: US 4880 Onwards        Pages: 131
    Physiological Saline is a mixture of sodium chloride in water and has a number of uses in medicine. Applied to the affected area it is used to clean wounds, help remove contact lenses, and help with dry eyes. By injection into a vein it is used to treat dehydration such as from gastroenteritis and diabetic ketoacidosis. It is also used to dilute other medications to be given by injection. Note: In this report, the unit should be bottle or bag, which depends on the package of the p......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs